|Bid||39.40 x 2200|
|Ask||39.41 x 3200|
|Day's Range||39.39 - 39.84|
|52 Week Range||29.99 - 43.08|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||23.15|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||1.56 (3.90%)|
|Ex-Dividend Date||May 06, 2021|
|1y Target Est||42.69|
Novavax (NVAX) will be able to pursue emergency use authorization following new information that shows its COVID-19 vaccine is 90% effective.
The Covid vaccine from Novavax is practically as effective as those from Pfizer/BioNTech and Moderna—but easier to distribute. So why is the stock down?
The highly contagious type of the virus that causes Covid-19 has become the dominant variety in the U.S., and is expected to spread in the U.S.